Experts in dermatology comment on the impact of both roflumilast and tapinarof on the treatment of plaque psoriasis.
Mona Shahriari, MD, FAAD
Advertisement
Mona Shahriari, MD, FAAD, is an assistant clinical professor of dermatology at the Yale University School of Medicine, the associate director of clinical trials at CCD Research, and a senior editor for the Journal of Psoriasis and Psoriatic Arthritis. She also serves her local dermatology community as president of the Connecticut Society of Dermatology and Dermatologic Surgery
Articles by Mona Shahriari, MD, FAAD
Drs Alexandra K. Golant and Mona Shahriari review the efficacy data of roflumilast and tapinarof in the treatment of plaque psoriasis.
Expert dermatologists provide an overview of 2 newer topical treatments in the plaque psoriasis landscape, roflumilast and tapinarof.
Alexandra K. Golant, MD, and Mona Shahriari, MD, share thoughts on newer topical treatments as well as the role of topical treatments in managing plaque psoriasis.
Expert dermatologists discuss approaches to treatment selection for patients with plaque psoriasis, taking into account the impact of the therapy on quality of life.
Mona Shahriari, MD, comments on plaque psoriasis in skin of color populations, as well as the importance of shared decision-making between patient and dermatologist.
Alexandra K. Golant, MD, and Mona Shahriari, MD, provide an overview of the pathophysiology of plaque psoriasis, commenting on the many comorbidities that stem from this disease.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
